GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vita 34 AG (XTER:V3V) » Definitions » EBIT

Vita 34 AG (XTER:V3V) EBIT : €-21.81 Mil (TTM As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Vita 34 AG EBIT?

Vita 34 AG's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was €0.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was €-21.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vita 34 AG's annualized ROC % for the quarter that ended in Sep. 2023 was -0.19%. Vita 34 AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 1.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vita 34 AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -22.89%.


Vita 34 AG EBIT Historical Data

The historical data trend for Vita 34 AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vita 34 AG EBIT Chart

Vita 34 AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.50 2.05 -2.95 -26.25

Vita 34 AG Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -19.59 -1.69 -0.67 0.14

Competitive Comparison of Vita 34 AG's EBIT

For the Medical Care Facilities subindustry, Vita 34 AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vita 34 AG's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vita 34 AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vita 34 AG's EV-to-EBIT falls into.



Vita 34 AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-21.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vita 34 AG  (XTER:V3V) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vita 34 AG's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-0.356 * ( 1 - 12.99% )/( (175.732 + 157.18)/ 2 )
=-0.3097556/166.456
=-0.19 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Vita 34 AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.556/( ( (37.476 + max(-36.69, 0)) + (36.356 + max(-20.18, 0)) )/ 2 )
=0.556/( ( 37.476 + 36.356 )/ 2 )
=0.556/36.916
=1.51 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.771 + 3.394 + 2.234) - (8.798 + 0 + 46.291)
=-36.69

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.009 + 3.317 + 1.522) - (8.112 + 0 + 29.916)
=-20.18

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vita 34 AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-21.811/95.291
=-22.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vita 34 AG EBIT Related Terms

Thank you for viewing the detailed overview of Vita 34 AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vita 34 AG (XTER:V3V) Business Description

Traded in Other Exchanges
Address
Deutscher Platz 5a, Leipzig, DEU, D-04103
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.
Executives
Jakub Julian Baran Member of the Management Board
Dr. Alexander Granderath Supervisory Board

Vita 34 AG (XTER:V3V) Headlines

No Headlines